Compugen’s (CGEN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Compugen (NASDAQ:CGEN) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $4.00 price objective on the biotechnology company’s stock.

Separately, Weiss Ratings raised Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Compugen has an average rating of “Buy” and an average target price of $5.00.

Compugen Stock Performance

Shares of Compugen stock opened at $2.00 on Monday. The company has a 50-day simple moving average of $2.43 and a two-hundred day simple moving average of $2.43. The stock has a market capitalization of $189.10 million, a PE ratio of 5.26 and a beta of 2.78. Compugen has a 52-week low of $1.43 and a 52-week high of $3.23.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same quarter in the prior year, the company posted ($0.08) earnings per share. As a group, equities research analysts forecast that Compugen will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

Several large investors have recently bought and sold shares of CGEN. Bank Hapoalim BM bought a new position in Compugen during the 4th quarter valued at about $37,000. Calamos Advisors LLC bought a new stake in shares of Compugen in the first quarter worth approximately $63,000. Hillsdale Investment Management Inc. bought a new stake in shares of Compugen in the first quarter worth approximately $68,000. Glenmede Trust Co. NA grew its stake in shares of Compugen by 187.5% in the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 22,500 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Compugen in the second quarter worth approximately $110,000. 12.22% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system’s ability to recognize and attack tumors.

Compugen’s pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.